



## Current Management of Castration-Resistant Prostate Cancer (CRPC)

Guest Editors:

**Prof. Dr. Martin Bögemann**  
Universitätsklinikum Münster,  
Munster, Germany

**Prof. Dr. Tilman Todenhöfer**  
Studienpraxis Urologie,  
Nürtingen, Germany

Deadline for manuscript  
submissions:  
**closed (31 May 2023)**

### Message from the Guest Editors

Dear Colleagues,

In recent years, the treatment of castration-resistant prostate cancer has witnessed dramatic advances. Currently, the inhibition of androgen receptor signaling, chemotherapy, and radioligand therapies in various sequences are the mainstay of therapy. However, sooner or later, primary or secondary resistance against any given therapy inevitably occurs. Castration-resistant prostate cancer is still incurable, and accounts for nearly all prostate cancer-related deaths. Understanding the genetic and biological mechanisms leading to therapy resistance and sustaining progression is crucial to achieving further advances in the sequencing of available drugs and management of castration-resistant prostate cancer in general. Any experimental and clinical work potentially relevant to this Special Issue will be carefully considered for inclusion.

Prof. Dr. Martin Bögemann

Prof. Dr. Tillmann Todenhöfer

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)